Head Cardiology Division & CV Research Unit at Sanatorio Anchorena Itoiz|Prof of Medicine @usal @UBAMedicina|HF|Advanced Cardiac Imaging Specialist at ICBA
🔥🫀 Inflammation is no longer a hypothesis—it’s a therapeutic target
The 2025 ACC Scientific Statement on Inflammation and Cardiovascular Disease marks a turning point: inflammation is now recognized as a causal, measurable, and actionable driver of cardiovascular risk, not just a bystander .
🧠 Key paradigm shift
Even in statin-treated patients with optimal LDL-C, residual inflammatory risk—best captured by high-sensitivity C-reactive protein (hsCRP)—strongly predicts recurrent events and cardiovascular death. In fact, post-statin hsCRP is often more prognostic than LDL-C itself.
📏 Measure what you want to treat
The statement makes a bold recommendation:
👉 Near-universal hsCRP screening in both primary and secondary prevention.
hsCRP <1 mg/L → low risk
1–3 mg/L → intermediate risk
3 mg/L → high inflammatory risk
Persistently elevated hsCRP (>2 mg/L) identifies patients who remain vulnerable despite guideline-directed therapy.
💊 Anti-inflammatory therapies: what works (and what doesn’t)
❌ Broad immunosuppression failed (e.g. methotrexate in CIRT).
✅ Targeted inflammation inhibition works:
Canakinumab (CANTOS) proved the inflammation hypothesis—reducing events without lowering LDL-C.
Low-dose colchicine (0.5 mg/day) reduced recurrent CV events by ~25% and is now FDA-approved for secondary prevention.
🚧 New frontiers: IL-6 inhibition (ziltivekimab, clazakizumab) in CKD, HFpEF, ACS—results expected soon.
🧘♂️ Lifestyle is anti-inflammatory medicine
Mediterranean/DASH diets 🥗, omega-3 intake 🐟, exercise 🏃♀️, weight control, and smoking cessation are explicitly framed as anti-inflammatory interventions, not just “healthy habits.”
🖼️ Imaging: promising, not ready
Advanced imaging of vascular inflammation (e.g. perivascular fat attenuation index) is exciting—but not yet for routine clinical use.
🔮 Bottom line
Atherosclerosis is an inflammatory disease with lipid involvement.
The time has come to treat cholesterol and inflammation—with biomarkers, lifestyle, and targeted therapies—moving cardiovascular prevention into a new era 🚀
Qué placer es siempre ir al congreso @secardiologia, compartir, aprender y reencontrarte con los viejos y nuevos amigos. Este año contento además por haber tenido el honor de presentar las guías @escardio Peri&Miocarditis. Vuelta a casa con una 🙂
Durante el ámbito del ESC25 Madrid. Fui a buscar mi Diploma de Máster en RMC, que lo tenía relegado desde 2023. Le puse muchísimo esfuerzo y sacrificio. Quisiera agradecer por acá solamente a mi familia, que me aguantaron horas estudiando a full.
Este acto es solo un avance más, en la formación médica continua en la modalidad de
Imágenes cardiacas avanzadas multiimagen donde el paciente siempre debe ser el centro y lo más importante.
The following review will provide a comprehensive overview of the finely regulated endogenous antithrombotic mechanisms responsible for maintaining the haemostatic balance and preventing intravascular thrombosis. Need it to read! https://t.co/4POplyqlb2
🔵¿Cuál es la situación de los #cardiólogos en #Argentina🇦🇷? Encuesta del Área de #Políticas de #Salud.
🔸393 cardiólogos
🔹Edad x̅ 56 ± 9
🔸50 % ámbitos sin residencia
🔹>90 % piensa q está mal remunerado
🔸≈90 % considera q la residencia es el mejor sistema formativo
SAC24 - Abriendo La Rural - Parte 2. Gran sesión vivimos el día 1. Elevado nivel de discusión. Gracias al Comité Científico del Congreso SAC24 por la invitación. Lo disfruté mucho 👏🏻👏🏻👏🏻
50 Congreso Argentino de Cardiología SAC24.
Este 16/10 a las 8:30 AM, trataré de convencerlos del valor que tienen las Imágenes Cardíacas de Stress en la evaluación de los pacientes luego de un procedimiento de revascularizacion (Stent o Cirugía). Quedan todos invitados!!!